Hoffmann-la Roche Inc.

Pharmacopeia Drug Discovery, Inc.

Berlex Laboratories, Inc.

Pepsico, Inc.

Other

Pharmacopeia Inc.

Bristol-myers Squibb Compnay

Roche Palo Alto LLC

Berlax Laboratories, Inc.

Pharmacopela Drug Discovery, Inc.

Shawn David Erickson

John J Baldwin

Roland Ellwood Dolle

Michael H J Ohlmeyer

Gary Bruce Phillips

Michael M Morrissey

David D Davey

Zuchun Zhao

James J Devlin

Vidyadhar Madhav Paradkar

Damian O Arnaiz

Bin Ye

John V Parkinson

Gonghua Pan

Kirk McMillan

Kyungjin Kim

Zhi Chen

Yimin Qian

Hans G Richter

Henrietta Dehmlow

Sherrie Lynn Pietranico-Cole

Rainer Eugen Martin

Ulrike Obst Sander

Caterina Bissantz

Paul Gillespie

Eric Mertz

Patrizio Mattei

Christophe Claude Galopin

Christine E Brotherton-Pleiss

Christoph Ullmer

Laura Nattress

Jefferson Wright Tilley

Sung-Sau So

Jeffrey John Letourneau

Hongju Li

Robert James Weikert

Prabha Saba Karnachi

Katerina Leftheris

Alaric J Dyckman

Stephen T Wrobleski

Wei Li

Peter Michael Wovkulich

Elbert Chin

Edward McDonald

Qingjie Ding

Kevin Richard Guertin

Ian Henderson

Stephen Deems Gabriel

Axel Metzger

Yvonne Class Shimshock

Gulzar Ahmed

Kevin Joseph Moriarty

James Inglese

Qiang Zhang

Lin Yi

Zahid Hussain

Joseph Anthony Bilotta

James Wen

Junjun Wu

William Bonorden

Joseph P Lyssikatos

Jean-Marc Plancher

Anthony A Estrada

Koc-Kan Ho

Huifen Chen

Thomas Lee

Steven Gregory Mischke

Robert Alan Goodnow, Jr

Robert Francis Kester

Nader Fotouhi

Allen John Lovey

Shaoqing Chen

Dirk Leysen

Jaap Van Der Louw

Stephan Bachmann

Jing Zhang

Kshitij Chhabilbhai Thakkar

Buelent Kocer

Steven Joseph Berthel

Nan Jiang

Steven G Kultgen

Christopher Mark Riviello

Lida Qi

Stephen Gravina

Adolph C Bohnstedt

Warren William McComas

Chun Ma

Yuliya Kurash

Paolo Giovanni Martino Conti

Hong Wang

Feng Chi

Richard Jones

Yu-Wen Feng

Ting Wang

Dramane Ibrahim Laine

JohnMark Derryberry

Christoph Ulmer

Edward Mcdonald

The present disclosure provides high purity rebaudioside J and methods of making high purity rebaudioside J. The application also provides the use of rebaudioside J as a sweetener, and in particular, the use in beverages.

Compositions comprising rebaudioside J

The present disclosure provides novel sweetener compositions comprising a compound having a structure according to Formula I: wherein R, R, R, and Rare described herein. Also provided are methods of modulating sweetness profile of a product by adding a compound of Formula I to the product, such as a beverage product or a food product. For example, the compound described herein can be added to increase the overall sweetness of a nutritive sweetener sweetened beverages; decrease the sweetness time-of-onset for high potency sweeteners such as rebaudioside A; decreasing bitter, metallic and licorice off-notes of high potency sweeteners; and improve the sweet quality of sweetened products.

Glucosyringic acid analogs as sweetness profile modifiers

The present disclosure provides novel compounds that are steviol derivatives. The compounds generally can be characterized by a structure according to Formula I: wherein R, A, L, and Gare described herein. Also provided are sweetener compositions comprising the compound described herein either as a sweetener or a sweetener enhancer. Additionally, the compound or the sweetener composition can be included in a product such as a beverage product or a food product, which can reduce the amount of sweetener in the product required to achieve the same sweetness level in an otherwise identical product not including the compound or the sweetener composition.

Rebaudioside analogs

This invention relates to novel 3-aminopyridines of the formula wherein B, Band Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

3-amino-pyridines as GPBAR1 agonists

The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

Antiviral compounds

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R, R, R, R, R, Rand Rare defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted sulfonamide compounds

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

The invention is concerned with a compound of formula (I) wherein R1, R2, R2', R3, R3&#x2032; are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Imidazopyridine derivatives

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) can be used as medicament.

6-aminoindole derivatives as TRP channel antagonists

The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

Substituted carbamate compounds

The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Acetamide derivatives

The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.

Substituted phenylcarbamate compounds

The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compound of formula (I) as well as pharmaceutical compositions containing such compounds. The compound of formula (I) are SCD1 inhibitors and may be useful in treating cancer. 

Substituted isoxazole amide compounds as inhibitors of stearoyl-CoA desaturase 1 (SCD1)

Growing community of inventors

New York, NY, United States of America

Shawn David Erickson